Related Experiment Video
Updated: Oct 3, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Gastrin antagonists in the treatment of gastric cancer
1Department of Surgery, Queens Medical Centre, University of Nottingham, UK.
Abstract:
The polypeptide hormone, gastrin, is known to promote both the in vitro and in vivo growth of human gastric cancer. This proliferative activity has been shown to be mediated by high affinity, membrane-associated receptors. This has led to the development of agents with the ability to antagonise gastrin receptor binding, which have been evaluated for their potential clinical value. Other anti-gastrin therapies have been investigated. As gastrin may act as an autocrine mediator of gastric tumor cell proliferation, anti-secretory agents have been evaluated, as have agents which induce the production of neutralising anti-gastrin antibodies in situ.
Insights
Gastrin fuels human gastric cancer growth via specific receptors. Therapies targeting gastrin's proliferative effects, including receptor antagonists and anti-secretory agents, are under investigation for clinical use.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Gastrin, a polypeptide hormone, significantly promotes human gastric cancer cell proliferation.
- Gastrin's growth-promoting effects are mediated by high-affinity, membrane-associated receptors on cancer cells.
- Gastrin may function as an autocrine mediator, stimulating gastric tumor cell proliferation.
Purpose of the Study:
- To explore therapeutic strategies targeting the gastrin pathway in human gastric cancer.
- To evaluate agents that antagonize gastrin receptor binding for potential clinical application.
- To investigate alternative anti-gastrin therapies, including anti-secretory agents and those inducing anti-gastrin antibodies.
Main Methods:
- Development and evaluation of gastrin receptor antagonists.
- Investigation of anti-secretory agents to reduce gastrin levels.
- Exploration of therapeutic agents that stimulate the in situ production of neutralizing anti-gastrin antibodies.
Main Results:
- Gastrin receptor antagonists have been developed and evaluated for clinical potential.
- Anti-secretory agents have been investigated as a therapeutic approach.
- Agents inducing anti-gastrin antibodies in situ are also under study.
Conclusions:
- Targeting the gastrin pathway presents a promising therapeutic avenue for human gastric cancer.
- Multiple anti-gastrin strategies, including receptor blockade and modulation of gastrin levels, are being explored.
- Further research into these therapies may lead to novel treatments for gastric cancer.
More Related Videos
06:21Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
03:32Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
Published on: December 27, 2024
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...